SC Pharmaceuticals announced that it expects a net loss attributable to shareholders of the listed company for the fiscal year 2024 to be between 55 million and 80 million yuan, a decrease of 8.39% to 57.66% compared to the same period last year. It is expected that the net profit after deducting non-recurring gains and losses will be a loss of 58.37 million to 83.37 million yuan, a decrease of 141.79% to 245.36% compared to the same period last year. The expected operating revenue is between 150 million and 190 million yuan, with the operating revenue after deductions expected to be between 140 million and 180 million yuan. The company's stock trading may be subject to delisting risk warnings after the disclosure of the 2024 annual report